The complex interplay between these hormones and growth, as well as their roles in regulating energy balance and body composition, suggest that modulating GH and IGF-1 levels may be a promising strategy for combating obesity and its associated comorbidities. The gene discussed is IGF1; the disease is obesity due to melanocortin 4 receptor deficiency.